PDF
ePub
Citation
Print
Abstract
Purpose
The role of different galectins in the pathogenesis of different types of malignancy is now being intensely investigated. In this study, authors investigated the level of galectin-1 expression in human breast cancer tissue to define its relationship to the tumor invasiveness and tumor progression.
Methods
Formalin-fixed, paraffin-embedded tissues from 79 randomly selected breast cancer patients were used to perform immunohistochemical staining for galectin-1. The primary antibody was diluted mouse monoclonal antibody against galectin-1. The staining results were then interpreted by an experienced pathologist, and the results were compared between the groups having different pathologic variables.
Results
In breast cancer patients, galectin-1 was diversely expressed in the cancer tissue. Galectin-1 was expressed in both cancer cells and cancer-associated stromal cells. The levels of galectin-1 expression in cancer-associated stromal cells were higher in patients with invasive carcinoma (p = 0.001), in patients with advanced T stages (p = 0.007), and in patients with advanced TNM stages (p = 0.007). The galectin-1 expression in cancer-associated stromal cells was also higher in patients with lymph node metastasis and advanced N stages, but did not reach a statistically significant level. The galectin-1 expression in cancer cell did not have any correlation with pathologic variables.
Conclusion
This is the first study that has demonstrated the relationship of galectin-1 expression with the tumor invasiveness and tumor progression in human breast cancer. Further large-scaled studies are needed to define the prognostic value of galectin-1 in breast cancer patients, and the exact role of galectin-1 should be investigated more thoroughly.
References
1. Sharon N, Lis H. History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology. 2004. 14:53R–62R.
2. Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F. Introduction to galectins. Glycoconj J. 2004. 19:433–440.
3. Rabinovich GA, Toscano MA, Ilarregui JM, Rubinstein N. Shedding light on the immunomodulatory properties of galectins: novel regulators of innate and adaptive immune responses. Glycoconj J. 2004. 19:565–573.
4. Almkvist J, Karlsson A. Galectins as inflammatory mediators. Glycoconj J. 2004. 19:575–581.
5. van den Brule F, Califice S, Castronovo V. Expression of galectins in cancer: a critical review. Glycoconj J. 2004. 19:537–542.
6. Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim Biophys Acta. 2002. 1572:285–293.
7. Castronovo V, Van den Brule FA, Jackers P, Clausse N, Liu FT, Gillet C, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol. 1996. 179:43–48.
8. Idikio H. Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol. 1998. 12:1287–1290.
9. Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res. 2005. 11:2962–2968.
10. Hirabayashi J, Kasai K. The family of metazoan metal-independent beta-galactoside-binding lectins: structure, function and molecular evolution. Glycobiology. 1993. 3:297–304.
11. Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta. 2002. 1572:263–273.
12. Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, Tahara E. Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer. 1994. 56:474–480.
13. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer. 1999. 81:519–526.
14. Schoeppner HL, Raz A, Ho SB, Bresalier RS. Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer. 1995. 75:2818–2826.
15. Sanjuan X, Fernandez PL, Castells A, Castronovo V, van den Brule F, Liu FT, et al. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology. 1997. 113:1906–1915.
16. Gabius HJ, Brehler R, Schauer A, Cramer F. Localization of endogenous lectins in normal human breast, benign breast lesions and mammary carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol. 1986. 52:107–115.
17. Moon BK, Lee YJ, Battle P, Jessup JM, Raz A, Kim HR. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am J Pathol. 2001. 159:1055–1060.
18. Song YK, Billiar TR, Lee YJ. Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am J Pathol. 2002. 160:1069–1075.
19. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res. 1999. 59:4148–4154.
XML Download